You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 280 No. 19, November 18, 1998 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Cardiology
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (49)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular Interventions, Other
 •Surgical Interventions
 •Cardiovascular/ Cardiothoracic Surgery
 •Transplantation
 •Cardiac Transplantation
 •Cardiovascular Intervention
 •Immunology, Other
 •Alert me on articles by topic

Current Status of Cardiac Transplantation

Sharon A. Hunt, MD

JAMA. 1998;280:1692-1698.

Cardiac transplantation, first introduced 30 years ago, has become a widely used and increasingly important procedure for treatment of truly end-stage heart disease. Current use is limited strictly by donor supply, making selection of appropriate recipients an important ethical and societal issue. Survival rates after transplantation rose in the 1980s with the use of cyclosporine and have remained relatively consistent since then, although recipients older than 65 years or younger than 1 year have lower survival rates than recipients of other ages. Although immunosuppressive drugs have helped establish cardiac transplantation as a successful procedure, risks of opportunistic infection and rejection, as well as coronary arteriopathy, have led to development of new immunosuppressive agents currently under study. Future alternatives to the current technology of cardiac allotransplantation may include xenotransplantation and/or nonbiological replacement of the heart with mechanical devices.


From the Stanford University Medical Center, Stanford, Calif.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nontransplant Surgical Options for Heart Failure
Spoor and Bolling
Card Surg Adult 2008;3:1639-1648.
FULL TEXT  

Functional Properties of Human Embryonic Stem Cell-Derived Cardiomyocytes: Intracellular Ca2+ Handling and the Role of Sarcoplasmic Reticulum in the Contraction
Dolnikov et al.
Stem Cells 2006;24:236-245.
ABSTRACT | FULL TEXT  

Heart Failure
Eltzschig et al.
NEJM 2003;349:1002-1004.
FULL TEXT  

Human embryonic stem cells for cardiovascular repair
Nir et al.
Cardiovasc Res 2003;58:313-323.
ABSTRACT | FULL TEXT  

Nontransplant Surgical Options for Heart Failure
Badhwar and Bolling
Card Surg Adult 2003;2:1515-1526.
FULL TEXT  

Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart
Suzuki et al.
J. Thorac. Cardiovasc. Surg. 2001;122:759-766.
ABSTRACT | FULL TEXT  

Intracoronary Infusion of Skeletal Myoblasts Improves Cardiac Function in Doxorubicin-Induced Heart Failure
Suzuki et al.
Circulation 2001;104:I-213-217.
ABSTRACT | FULL TEXT  

Partial aortic valve fusion induced by left ventricular assist device
Rose et al.
Ann. Thorac. Surg. 2000;70:1270-1274.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.